Xenetic Biosciences Inc Share Price Nasdaq
Equities
US9840152063
Biotechnology & Medical Research
Sales 2024 * | 1.76M 2.23M 186M | Sales 2025 * | 1.44M 1.82M 152M | Capitalization | 4.81M 6.1M 510M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.08M -424M | Net income 2025 * | -7M -8.88M -742M | EV / Sales 2024 * | 2.74 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
-4.12
x | P/E ratio 2025 * |
-5.42
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 03/17/03 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14/17/14 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |